Answers are grounded in this paper and cite their sources.
Introduction: Despite advances and new treatment options, advanced urothelial carcinoma (aUC) remains very challenging to treat and has a poor prognosis. However, deeper knowledge of the molecular landscape of aUC has enabled the identification of potential biologic drivers, putative biomarkers, and therapeutic targets. The purpose of this review is to discuss the evolving field of precision oncology and emerging biomarkers in the treatment of aUC.Areas covered: This review discusses the current molecular landscape, precision oncology strategies, putative molecular targets and biomarkers, and the future directions of precision therapy in aUC.Expert opinion: Precision approaches in aUC have significant challenges due to molecular heterogeneity, clonal evolution, and genomic instability. However, technological advances, robust interrogation of molecular biology, and discovery of new therapeutic agents have heralded a new era of developmental therapeutics in aUC. The emerging broader use of next-generation sequencing (NGS) of tumor tissue and cell-free circulating tumor DNA (ctDNA) paired with novel therapies tested in clinical trials provide promising Precision Oncology strategies for this very challenging malignancy.
No takes yet. Share an insight, caveat, or question.
Schiff et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: